| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sam Padamadan Josep. Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional Disorder. Indian journal of psychological medicine. vol 38. issue 3. 2016-06-23. PMID:27335526. |
hence, in the absence of a competing d2 antagonist and the presence of dopamine (the natural agonist), aripiprazole could act as a functional antagonist and thus elevate prolactin levels. |
2016-06-23 |
2023-08-13 |
Not clear |
| Ilse C A Bakker, Chris D Schubart, Pierre M J Zelisse. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole. Endocrinology, diabetes & metabolism case reports. vol 2016. 2016-06-10. PMID:27284453. |
in this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. |
2016-06-10 |
2023-08-13 |
Not clear |
| Yojiro Umezaki, Miho Takenoshita, Akira Toyofuk. Low-dose aripiprazole for refractory burning mouth syndrome. Neuropsychiatric disease and treatment. vol 12. 2016-06-09. PMID:27279742. |
it could be supposed that the efficacy of aripiprazole is caused by dopamine stabilization in this case, and bms might have a subtype that is reactive to aripiprazole. |
2016-06-09 |
2023-08-13 |
Not clear |
| Roberto Maggio, Marco Scarselli, Marta Capannolo, Mark J Milla. Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 9. 2016-06-08. PMID:25453482. |
we highlight the binding profiles and mechanisms of interaction with d3-d3 homomers and d3-d2 heteromers of: first, the pet ligand and potent agonist [(11)c]-(+)-phno; second, the novel, bitopic/allosteric dopamine d3 receptor antagonist, sb269,652; and third, diverse partial agonists like antipsychotic and aripiprazole. |
2016-06-08 |
2023-08-13 |
Not clear |
| Alanna J Propst, G Eric Jarvis, Howard C Margoles. Aripiprazole-Induced Hypoprolactinemia in an Adult Male with First-Episode Psychosis. Clinical schizophrenia & related psychoses. vol 9. issue 4. 2016-05-12. PMID:25711510. |
aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine d2 receptors. |
2016-05-12 |
2023-08-13 |
Not clear |
| Hamed Shafaroodi, Simin Oveisi, Mahsa Hosseini, Hossein Niknahad, Leila Moez. The effect of acute aripiprazole treatment on chemically and electrically induced seizures in mice: The role of nitric oxide. Epilepsy & behavior : E&B. vol 48. 2016-05-05. PMID:26037847. |
aripiprazole is an antipsychotic drug which acts through dopamine and serotonin receptors. |
2016-05-05 |
2023-08-13 |
mouse |
| Hamed Shafaroodi, Simin Oveisi, Mahsa Hosseini, Hossein Niknahad, Leila Moez. The effect of acute aripiprazole treatment on chemically and electrically induced seizures in mice: The role of nitric oxide. Epilepsy & behavior : E&B. vol 48. 2016-05-05. PMID:26037847. |
dopaminergic and serotonergic systems relate to nitric oxide, and aripiprazole also has effects on dopamine and serotonin receptors. |
2016-05-05 |
2023-08-13 |
mouse |
| Christian Agudelo, Howard J Aizenstein, Jordan F Karp, Charles F Reynold. Applications of magnetic resonance imaging for treatment-resistant late-life depression. Dialogues in clinical neuroscience. vol 17. issue 2. 2016-04-29. PMID:26246790. |
neuroimaging also has the potential to similarly inform treatment response variability from treatment with aripiprazole (dopamine modulator) and buprenorphine (opiate modulator). |
2016-04-29 |
2023-08-13 |
Not clear |
| Bo Pan, Jiezhong Chen, Jiamei Lian, Xu-Feng Huang, Chao Den. Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats. PloS one. vol 10. issue 7. 2016-04-19. PMID:26162083. |
unique effects of acute aripiprazole treatment on the dopamine d2 receptor downstream camp-pka and akt-gsk3β signalling pathways in rats. |
2016-04-19 |
2023-08-13 |
rat |
| Bo Pan, Jiezhong Chen, Jiamei Lian, Xu-Feng Huang, Chao Den. Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats. PloS one. vol 10. issue 7. 2016-04-19. PMID:26162083. |
although aripiprazole was developed as a dopamine d2 receptor (d2r) partial agonist, all other d2r partial agonists that aimed to mimic aripiprazole failed to exert therapeutic effects in clinic. |
2016-04-19 |
2023-08-13 |
rat |
| Erin W Tuplin, Marlaina R Stocco, Matthew R Holaha. Attenuation of MK-801-induced behavioral perseveration by typical and atypical antipsychotic pretreatment in rats. Behavioral neuroscience. vol 129. issue 4. 2016-04-14. PMID:26052791. |
the behavioral effect of aripiprazole may be due to its a) binding to presynaptic dopamine receptors at the midrange dose decreasing dopamine output and b) binding to postsynaptic dopamine receptors at the higher dose increasing dopamine tone. |
2016-04-14 |
2023-08-13 |
rat |
| Jun Gao, Rongyin Qin, Ming L. Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function. Journal of psychopharmacology (Oxford, England). vol 29. issue 4. 2016-03-11. PMID:25586399. |
the present study investigated how repeated administration of aripiprazole (a novel antipsychotic drug) alters its behavioral effects in two behavioral tests of antipsychotic activity and whether this alteration is correlated with an increase in dopamine d2 receptor function. |
2016-03-11 |
2023-08-13 |
rat |
| Masayuki Takase, Nobuhisa Kanahara, Yasunori Oda, Hiroshi Kimura, Hiroyuki Watanabe, Masaomi Iy. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. Journal of psychopharmacology (Oxford, England). vol 29. issue 4. 2016-03-11. PMID:25735995. |
dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. |
2016-03-11 |
2023-08-13 |
Not clear |
| Masayuki Takase, Nobuhisa Kanahara, Yasunori Oda, Hiroshi Kimura, Hiroyuki Watanabe, Masaomi Iy. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. Journal of psychopharmacology (Oxford, England). vol 29. issue 4. 2016-03-11. PMID:25735995. |
the administration of aripiprazole (ari), a dopamine partial agonist, could provoke abrupt psychotic worsening in patients with schizophrenia. |
2016-03-11 |
2023-08-13 |
Not clear |
| Marrit K de Boer, Stynke Castelein, Durk Wiersma, Robert A Schoevers, Henderikus Knegterin. The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings. Schizophrenia bulletin. vol 41. issue 3. 2016-01-29. PMID:25721311. |
also, the addition of a dopamine agonist, aripiprazole, or a phosphodiesterase-5 inhibitor has shown some promising results, but evidence is currently scarce. |
2016-01-29 |
2023-08-13 |
Not clear |
| Eiji Kirin. Use of aripiprazole for delirium in the elderly: a short review. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society. vol 15. issue 1. 2016-01-01. PMID:25514894. |
compared to other antipsychotics, aripiprazole differs in pharmacological activity because it exerts its effect as a dopamine d2 partial agonist. |
2016-01-01 |
2023-08-13 |
Not clear |
| Fabricio A Moreira, Jeffrey W Dalle. Dopamine receptor partial agonists and addiction. European journal of pharmacology. vol 752. 2015-12-17. PMID:25724788. |
recent research indicates that the dopamine d2 receptor partial agonists, such as aripiprazole, also shows useful ancillary efficacy in several animal models of psychostimulant and opioid addiction. |
2015-12-17 |
2023-08-13 |
Not clear |
| Marek Kucka, Melanija Tomić, Ivana Bjelobaba, Stanko S Stojilkovic, Dejan B Budimirovi. Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs. Scientific reports. vol 5. 2015-12-09. PMID:25754735. |
in the presence of dopamine, paliperidone rescued camp/calcium signaling and prolactin release in a concentration-dependent manner, whereas aripiprazole was only partially effective. |
2015-12-09 |
2023-08-13 |
rat |
| Marek Kucka, Melanija Tomić, Ivana Bjelobaba, Stanko S Stojilkovic, Dejan B Budimirovi. Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs. Scientific reports. vol 5. 2015-12-09. PMID:25754735. |
in the absence of dopamine, paliperidone stimulated camp/calcium signaling and prolactin release, whereas aripiprazole inhibited signaling and secretion more potently but less effectively than dopamine. |
2015-12-09 |
2023-08-13 |
rat |
| Marek Kucka, Melanija Tomić, Ivana Bjelobaba, Stanko S Stojilkovic, Dejan B Budimirovi. Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs. Scientific reports. vol 5. 2015-12-09. PMID:25754735. |
forskolin-stimulated camp production was facilitated by paliperidone and inhibited by aripiprazole, although the latter was not as effective as dopamine. |
2015-12-09 |
2023-08-13 |
rat |